Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s377697
Abstract: Abstract Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the… read more here.
Keywords: ibrutinib; ibrutinib associated; associated cardiotoxicity; cardiotoxicity ... See more keywords
Cardiovascular Magnetic Resonance in Early Detection of Radiation Associated Cardiotoxicity With Chest Radiation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.867479
Abstract: Background Chest radiation therapy (RT) is known to be associated with cardiotoxicity. However, the changes in myocardial tissue characterization with radiation-induced cardiotoxicity are not well-understood. Objectives This study sought to assess the changes in left… read more here.
Keywords: chest radiation; associated cardiotoxicity; tissue characterization; cardiovascular magnetic ... See more keywords
Genetics of Anthracycline-Associated Cardiotoxicity
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.867873
Abstract: Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic… read more here.
Keywords: anthracycline associated; associated cardiotoxicity; act; genetics anthracycline ... See more keywords